Michael Goodman, MD
Psychiatry · Omaha, NENPI 1992770044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $443 and has fallen 65.3% since, to $154 in 2025.
Across 96 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neos Therapeutics, LP$232
- Lundbeck LLC$223
- Sunovion Pharmaceuticals Inc.$221
- Takeda Pharmaceuticals U.S.A., Inc.$166
- Ironshore Pharmaceuticals Inc.$144
- Supernus Pharmaceuticals, Inc.$119
- plus $611 from 12 others
What the payments were for
- Food & beverage$1,713100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neos Therapeutics, LP | 13 | $232 |
| Lundbeck LLC | 12 | $223 |
| Sunovion Pharmaceuticals Inc. | 15 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $166 |
| Ironshore Pharmaceuticals Inc. | 9 | $144 |
| Supernus Pharmaceuticals, Inc. | 3 | $119 |
| AbbVie(2 entities) | 6 | $114 |
| Corium, LLC | 5 | $114 |
| Adlon Therapeutics L.p. | 7 | $108 |
| Tris Pharma Inc | 4 | $83 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Shire North American Group Inc | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $13 |
| Neuronetics, Inc. | 1 | $11 |
How this compares
$1,717 in reported general payments places this provider in the 80th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paroxetine Hcl | 21 | $391 |
| Fluoxetine Hcl | 17 | $121 |
| Sertraline Hcl | 16 | $95 |
| Alprazolam | 31 | $75 |
| Escitalopram Oxalate | 11 | $63 |
| Lamotrigine | 11 | $57 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Omaha
- Vithyalakshmi SelvarajOmaha$1.2M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Syed SattarOmaha$16K
- Michael SedlacekOmaha$15K
- Sriram RamaswamyOmaha$13K
- Elizabeth FitzpatrickOmaha$10K
- Praveen FernandesOmaha$5K
- Natalie BakerOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.